Novo Nordisk Faces Job Cuts Amid Ozempic Turmoil and Increased Competition

Denmark’s pharmaceutical powerhouse Novo Nordisk is set to axe 9000 jobs, marking one of the most substantial workforce reductions in its history, as the company battles a steeply declining share price and a wave of stiff competition in the market for weight-loss drugs.

The layoffs, including 5000 positions in Denmark, form part of a strategic restructuring aimed at delivering savings of 8 billion Danish Krone (£930 million). The reduction accounts for more than 11 percent of the company’s total workforce as the firm seeks to bolster profitability amidst falling prices in the weight-loss and anti-obesity sector.

Chief Executive Mike Doustdar attributed the redundancies to a “more competitive and consumer-driven” market landscape. Growing rivalry, particularly from US competitor Eli Lilly, has unsettled Novo Nordisk’s dominance. Eli Lilly’s Mounjaro, for example, has posted stronger clinical results for obesity treatments, with trial subjects losing on average 21 percent of their body weight over eighteen months—outpacing Novo Nordisk’s offerings.

Since the commercial triumph of Ozempic and the subsequent launch of Wegovy, both based on the compound semaglutide, Novo Nordisk vaulted to a hefty $500 billion (£370 billion) valuation, at one stage surpassing the value of Denmark’s entire economy. However, shares have plunged nearly 50 percent this year, with as much as $70 billion wiped from the company’s capitalisation in a single day in June.

The drop has been compounded by the proliferation of copycat drugs in the United States, forcing Novo Nordisk to slash Ozempic’s American price by half. Simultaneously, regulatory pressures from former US President Donald Trump have demanded lower medication prices for Americans, intensifying the pressure on the firm’s margins. Novo Nordisk’s attempts to have US authorities ban imports of active pharmaceutical ingredients used in unauthorised replicas underscore the risk posed by the counterfeit market.

Instability at the top, including a change in chief executive earlier this year, has added to the company’s woes. The collapse in Novo Nordisk’s fortunes has had knock-on effects for the wider Danish economy, leading officials to revise national economic growth forecasts downward and incurring steep losses for pension funds heavily invested in the company’s shares.

The business warned that profit margins will narrow further this year due to one-off restructuring costs, but is targeting £930 million in savings by next year. Investors and industry observers are watching closely as Novo Nordisk plots its recovery in an ever more competitive global pharmaceutical market.